299. 嚢胞性線維症
[臨床試験数:1,592,薬物数:1,539(DrugBank:255),標的遺伝子数:81,標的パスウェイ数:162

Searched query = "Cystic fibrosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02273661
(ClinicalTrials.gov)
November 19, 201422/10/2014Evaluation of a Therapeutic Strategy Including Nebulised Liposomal Amphotericin B (Ambisome®) in Maintenance Treatment of Allergic Bronchopulmonary Aspergillosis (Cystic Fibrosis Excluded).Evaluation of a Therapeutic Strategy Including Nebulised Liposomal Amphotericin B (Ambisome®) in Maintenance Treatment of Allergic Bronchopulmonary Aspergillosis (Cystic Fibrosis Excluded)Allergic Bronchopulmonary AspergillosisDrug: Liposomal amphotericin B (Ambisome®);Drug: placeboPoitiers University HospitalNULLCompleted18 YearsN/AAll174Phase 2France
2EUCTR2010-019194-15-IT
(EUCTR)
12/05/201013/05/2010Esplorative study to evaluate the tolerability of Amphotericin B lipid complex (Abelcet) by aerosol in patients with Cystic Fibrosis and Allergic Bronchopulmonary Aspergillosis (ABPA) - NDEsplorative study to evaluate the tolerability of Amphotericin B lipid complex (Abelcet) by aerosol in patients with Cystic Fibrosis and Allergic Bronchopulmonary Aspergillosis (ABPA) - ND Cystic Fibrosis and Allergic Bronchopulmonary Aspergillosis (ABPA)
MedDRA version: 9.1;Level: SOC;Classification code 10021881
MedDRA version: 9.1;Level: PT;Classification code 10011762
Trade Name: ABELCET
INN or Proposed INN: Amphotericin B
AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONANULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Italy